EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani-Molky, Giselle Kidson-Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar und 6 weitere

Asia-Pacific Journal of Clinical Oncology · 2026-08 · 22 (4) · 573-583

DOI: 10.1111/ajco.70101 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 22.03.2026. Verfasst von Samantha Kurniawan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Hospital, Liverpool, Australia. Hauptthemen laut MEDLINE: Multiple Myeloma, Lenalidomide, Bortezomib, Dexamethasone. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to upfront anti‐CD38 therapy within the Asia‐Pacific. However, regimens proven efficacious in clinical trials utilize twice‐weekly bortezomib, which is now thought to confer unacceptable toxicity, particularly in transplant‐ineligible patients. There is a paucity of prospective data on RVD treatment schedules utilizing weekly bortezomib, which has implications for health care systems implementing standardized treatment based on clinical trial evidence.

Methods

Eighty‐three patients with newly diagnosed transplant‐ineligible multiple myeloma from six hospitals in Australia, received one of two RVD regimens utilizing weekly subcutaneous bortezomib (Modified SWOG and Modified RVD Lite) pragmatically adapted from their corresponding clinical trials. Baseline characteristics, response rates, toxicities, and survival were assessed.

Results

At a median follow‐up of 27.4 months, Modified SWOG achieved an ORR 91.4%, ≥ VGPR 71.4%, and 24‐month progression‐free survival (PFS) of 63.1% (95% CI: 47.6–83.5). Modified RVD Lite achieved an ORR 93.9%, ≥ VGPR 64.7%, and 24‐month PFS of 53.6% (95% CI: 39.1–73.4). Despite dose attenuation, significant toxicity was still seen overall with hospitalizations in 48.2% and premature cessation due to toxicity in 31.3%. Peripheral sensory neuropathy was lower than in published clinical trials, reported in 32 (38.6%) patients, with Grade 3 events in only 2 patients.

Conclusion

This study demonstrates that real‐world outcomes of weekly RVD regimens have comparable efficacy to published twice‐weekly regimens; however, toxicity remains a significant challenge in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaLenalidomideBortezomibDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleAgedMiddle AgedAustraliaAged, 80 and overDrug Administration Schedule

Stichwörter der Autor:innen

RVDVRDfrailtymyelomatransplant‐ineligible

Substanzen

LenalidomideBortezomibDexamethasone

Autor:innen und Institutionen

  • Liverpool Hospital, Liverpool, Australia.
  • School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Sydney, Australia.
  • St Vincent's Hospital, Darlinghurst, Australia.
  • Concord Repatriation General Hospital, Concord, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Royal Prince Alfred Hospital, Camperdown, Australia.

Zitieren

APA

Kurniawan, S., Hwang, A., Doo, N. W., King, T., Bryant, C., Zhang, J., Whelan, K., Fani-Molky, P., Kidson-Gerber, G., Bosco, A., Hamad, N., Parmar, G., Kwok, F., Lai, S., Ling, S., Ho, P. J., McCaughan, G., & Bryant, A. (2026). Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study. Asia-Pacific Journal of Clinical Oncology, 22(4), 573-583. https://doi.org/10.1111/ajco.70101

Vancouver

Kurniawan S, Hwang A, Doo NW, King T, Bryant C, Zhang J, et al. Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study. Asia-Pacific Journal of Clinical Oncology. 2026;22(4):573-583. doi:10.1111/ajco.70101

BibTeX
@article{Kurniawan2026,
  author = {Kurniawan, Samantha and Hwang, Angela and Doo, Nicole Wong and King, Tracy and Bryant, Christian and Zhang, Jennifer and Whelan, Kristina and Fani-Molky, Parisa and Kidson-Gerber, Giselle and Bosco, Annmarie and Hamad, Nada and Parmar, Gurdeep and Kwok, Fiona and Lai, Sam and Ling, Silvia and Ho, P Joy and McCaughan, Georgia and Bryant, Adam},
  title = {Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2026},
  volume = {22},
  number = {4},
  pages = {573--583},
  doi = {10.1111/ajco.70101}
}
Kostenlos starten →